5-Amino-1MQ Protocol Guide
5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in adipose tissue that regulates cellular energy metabolism. By inhibiting NNMT, 5-Amino-1MQ increases intracellular concentrations of NAD+ and S-adenosyl methionine (SAM), which promote energy expenditure, reduce fat cell size, and enhance metabolic activity. This protocol covers oral dosing at 50-100mg daily, cycling strategies, metabolic optimization timeline, and stacking with complementary compounds.
Protocol Overview
- Compound
- 5-Amino-1MQ (5-Amino-1-Methylquinolinium)
- Category
- Fat Loss / Metabolic Modulator
- Mechanism
- NNMT inhibitor; increases intracellular NAD+ and SAM, promoting energy expenditure and reducing lipogenesis in adipocytes
- Molecular Weight
- 159.19 g/mol
- Half-Life
- ~4-6 hours (estimated oral)
- Form
- Oral capsules (50mg typical)
- Route
- Oral
- Frequency
- 1-2x daily with meals
- Cycle Length
- 8-12 weeks on, 4 weeks off
Dosing Protocol
| Protocol | Dose | Frequency | Route | Duration |
|---|---|---|---|---|
| Introductory | 50 mg | 1x daily (AM with food) | Oral | 1 week |
| Standard | 50 mg | 2x daily (AM + PM with food) | Oral | 8-12 weeks |
| Advanced | 100 mg | 2x daily (AM + PM with food) | Oral | 8-12 weeks |
Key principle: Take with meals to improve absorption and reduce GI discomfort. Split dosing maintains more consistent NNMT inhibition throughout the day given the relatively short half-life.
Administration Guide
Oral Administration
- Form: Capsules (no reconstitution needed)
- With food: Take alongside a meal containing some dietary fat
- Timing: Morning and early afternoon preferred
- Avoid: Late evening dosing (may affect sleep via metabolic activation)
Storage & Handling
- Storage: Room temperature, away from moisture and light
- Shelf life: 12-18 months sealed
- Keep dry: Avoid humid environments
- Cycling: 8-12 weeks on, 4 weeks off to prevent tolerance
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Mild GI discomfort if taken without food
- Slight increase in body temperature (thermogenic effect)
- Headache during first few days (uncommon)
- Increased thirst
5-Amino-1MQ is generally well-tolerated in preclinical research. Most side effects are transient and dose-dependent.
Precautions
- Limited long-term human clinical data available
- Monitor liver enzymes during extended use
- Avoid combining with other NNMT-targeting compounds
- Not recommended during pregnancy or breastfeeding
Stacking Recommendations
Compatible Compounds
- AOD-9604: Complementary fat loss via hGH fragment pathway
- MOTS-c: Mitochondrial metabolic synergy
- CJC-1295/Ipamorelin: GH support for body recomposition
- NAD+ precursors: Further support for cellular energy metabolism
- L-Carnitine: Enhanced fatty acid transport
Popular Stacks
- Metabolic Stack: 5-Amino-1MQ 100mg/day + AOD-9604 300mcg/day
- Energy Stack: 5-Amino-1MQ 100mg/day + MOTS-c 10mg 3x/week
- Recomp Stack: 5-Amino-1MQ + CJC-1295/Ipamorelin at night
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Metabolic Panel | Fasting glucose, insulin, HbA1c | Baseline, Week 6, Week 12 |
| Lipid Panel | Total cholesterol, LDL, HDL, triglycerides | Baseline, Week 12 |
| Liver Function | ALT, AST, GGT, bilirubin | Baseline, Week 6, Week 12 |
| Body Composition | DEXA scan or BIA measurement | Baseline, Week 12 |
Monitoring liver function is particularly important with oral compounds. Track metabolic markers to quantify improvements in insulin sensitivity and lipid profiles.
Related Tools & Resources
